APLS
USDApellis Pharmaceuticals Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$20.400
Максимум
$20.610
Минимум
$19.440
Объем
5.10M
Фундаментальные показатели компании
Рыночная капитализация
2.5B
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
2.51M
Биржа
NMS
Валюта
USD
52-недельный диапазон
Связанные новости
Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $19
Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals with a Neutral and lowers the price target from $24 to $19.
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $52 to $45.
TD Cowen Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
TD Cowen analyst Phil Nadeau maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $50 to $45.
Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $52
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals with a Outperform and raises the price target from $50 to $52.
HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $57 to $45.
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary
Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $32
Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals from Equal-Weight to Overweight and raises the price target from $29 to $32.
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.